Evaluation of the sedative effect of sublingual lorazepam versus placebo in patients who are candidate for endoscopy

Evaluation of the sedative effect of sublingual lorazepam versus placebo in patients who are candidate for endoscopy: a double blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201611039014N130

Enrollment

114

Registered

2016-11-05

Start date

2016-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

candidate for endoscopy. During endoscopic examination

Interventions

Intervention 1: Intervention group: sublingual tablet lorazepam 2 mg single dose half hour before endoscopy. Intervention 2: Control group: placebo single dose half hour before endoscopy.

Treatment - Drugs

Placebo

Intervention group: sublingual tablet lorazepam 2 mg single dose half hour before endoscopy.

Control group: placebo single dose half hour before endoscopy

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: candidate for endoscopy; age of 18 to 55 years. Exclusion criteria: cardiopulmonary disease; neuropsychological disorders; sensitivity to lorazepam; body mass index above 30.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sedative effect of drug. Timepoint: half hour after treatment. Method of measurement: through physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohreh Seifi

Shahid Beheshti Hospital

zseifi861372@gmail.com+98 81 3838 0283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026